BioLife Sciences Inc.

Featured Company / BioLife Sciences Inc.

The coronavirus pandemic has raised awareness about health and wellness and what it takes to destroy resilient pathogens like those responsible for COVID-19 and all its Greek-alphabet-named variants. With 5.56 million deaths globally and over 331 million cases confirmed across all but four countries on Earth, essentially everyone on the planet is aware of the transmissibility and potential outcomes for contracting COVID-19.

From individuals to governments, standards and protocols are being implemented as part of “the new normal” to protect against viruses, fungi, parasites, and bacteria. Unsurprisingly, technology is playing a key role. These initiatives are right in the wheelhouse of BioLife Sciences Inc. (OTCPK: BLFE), an accelerator of companies and products with an initial focus on wellness, including antimicrobial technologies.

The flagship products in the BioLife product portfolio involve using leading-edge technologies, including copper infusion, to protect against pathogens. The company has also last month announced a transformational acquisition that will give revenue a shot in the arm.

Let’s Start with the Power of Copper

The phenomenon of copper-related health and wellness has been around for centuries. For starters, copper is an important mineral to the body taken in through a variety of foods and used in keeping nerve cells healthy, red blood cell production, immune system support, and more.

From an external perspective, the values of copper in many applications are trumpeted for the metal’s properties, including thermal regulation. Consider that NASA and armies around the world issue copper-impregnated clothing because of its insulation properties while remaining lightweight and breathable.

Blood circulation is another often heralded benefit of copper-infused products. During this time of the year with the NFL playoffs happening, it is not uncommon to see commercials where retired NFL legends serve as ambassadors for such products. Why? Because copper compression clothing is believed to be effective in alleviating poor circulation, which can help combat conditions like deep vein thrombosis, while reducing symptoms of inflammatory conditions, like arthritis. Again, thermal regulation is valuable in tissue repair and protection.

Another benefit of copper – and one that is more on point with warding off pathogens – is skin health. Copper is well known to promote healthy skin because of its antimicrobial properties, as well as its role in supporting collagen and elastin growth. In fact, the term “contact killing” originated with the knowledge that bacteria are destroyed when coming into contact with metallic copper surfaces. The antimicrobial benefits can be far reaching insomuch that destroying or limiting microbe growth under an array of conditions has positive benefits from preventing infections to purifying drinking water to eliminating foul odors.

There is also a growing body of evidence on the effectiveness of copper-impregnated fabric offering superior performance to today’s materials used in health services. So, while these products already have a place in healthcare, expanded uses supported by peer-reviewed clinical data present a unique opportunity for overlooked upside in a global environment where preventing and controlling pathogen transmissions is a top priority.

Mfusion: The Ultimate Coverage

To understand Mfusion requires the knowledge that many products today simply weave copper fibers into their products. This is not optimal, as it leaves gaps throughout the material. Mfusion infuses copper metal ions into every sub-bundle of the fabric filter, resulting in natural protection against bacteria and germs, which normally thrive when circulating in an enclosed room, or building.  The fabric helps to block out airborne particles, while any germs or viruses which are trapped in the filter fabric will come in contact with the copper ions and become deactivated over time.

BioLife’s Mfusion technology can apply to absolutely any textile, albeit face masks, bedding, pillow sheets, socks, gloves, shorts, t-shirts, hats, etc. Simply, if its cloth then BioLife can infuse it and amplify and create natural antimicrobial, antiviral, anti-odor, and antifungal benefits. The potential applications are wide ranging from fighting jock itch and acne to anti-aging possibilities.

Copper-Infused Facial Masks

Facing a global pandemic, BioLife put its technology to work, launching a line of copper-infused face masks as an answer to one of the most debated topics in America of whether or not masks work. Understand that with the cloth masks that most people wear daily, pathogens can live for days. Conversely, masks infused with copper provide continuous protection, while potentially providing several health benefits to the skin through copper’s anti-inflammatory and regenerative properties.

BioLife manufactures its face masks in North America and offers them in cotton and polyester blends in wholesale quantities.

Antimicrobial Air Filters: Masks for a House or Business

BioLife also launched a new antimicrobial air filter based upon its proprietary Mfusion technology. The BioLife Antimicrobial Air Filters are designed to durably clean the air and fight against airborne bacteria and viruses, providing consumers with the ability to help sanitize the air in their homes or workspaces for months at a time.

Mfusion technology leverages the natural antimicrobial benefits of copper ions, which have been shown to kill 99.99% of bacteria, fungi, and viruses.

BioLife Making Air Travel Safer

It used to be that most people were afraid to fly because of the (albeit miniscule) risk of a crash. Today, those fears have been replaced by virus concerns. BioLife entered this space in November 2020, inking an agreement with FLYGTA, an Ontario-based operator of a fleet of aircraft serving private travel, air ambulance, cargo, tourism, and aviation technologies, to become the exclusive supplier of electrostatic disinfection and cleaning services. Per the pact, BioLife agreed to conduct cleaning and disinfecting services for FLYGTA’s aircraft fleet and private lounges, operating out of district airports throughout Ontario, including Toronto's Billy Bishop Airport.

BioLife’s sanitation technology is designed to control bacterial, viral, and fungal populations on high-touch, high-traffic surfaces by reducing the number of germs on the treated areas. The company’s electrostatic systems turn disinfectant liquids into fine mist aerosols, subsequently applying a charge to each droplet so that they are attracted to surfaces through electrostatic forces greater than gravity. The result is a wrap-around effect for complete coverage, even in areas that would generally be difficult to clean.

The technology is scalable and versatile, able to be used with essentially any water-based disinfectant to meet the customer’s needs. With FLYGTA, BioLife used a natural essential oil and water-based sanitation solution known to be effective against SARS-CoV-2 (the coronavirus responsible for COVID-19) and strain 229E, a common human coronavirus. Customers can rest assured that while effective as a broad spectrum surface disinfectant, the product is also non-toxic, biodegradable, non-corrosive, odorless, and colorless, in other words: potent and environmentally-friendly.

“We are ready for the new wave of travel with this added safety measure. Antimicrobial protection is the smartest way forward.”
- Chris Nowrouzi, CEO of FLYGTA, on the BioLife agreement

BioLife Buying Health Box

On January 25th, BioLife said that it had inked a Letter of Intent to acquire Health Box LLC, an Arizona-based company specialized in advanced orthomolecular medicine and natural health products development and research. More precisely, Health Box provides a diverse mix of advanced orthomolecular and natural health products founded in extensive research focused on medicinal botanicals, micronutrients, dietary supplements, proprietary herbal blends, and apothecary style subscription services. Further, Health Box is an expert in the development of tinctures, oils, vitamins and hemp-derived cannabidiol (CBD) products.

“Orthomolecular” is a term coined in 1968 by molecular biologist and two-time Nobel Prize winner Dr. Linus Pauling. Coupling “ortho” (Green for “correct” or “right”) and “molecule, the word literally means the “right molecule.” The practice of orthomolecular medicine is characterized by evidence-based formulations providing the body with optimal amounts of substances natural to the body for the purpose of preventing and treating diseases and conditions.

The company is in the thick of a global herbal supplements market that has been accelerating amid heightened health and wellness awareness, where consumers have become increasingly proactive at bolstering immunity and looking for safe, natural alternatives to conventional drugs to stave off pathogens.

According to the company, the global herbal supplements market is projected to reach $86.74 billion by 2022 after 6.8% from 2016 to 2022. Single herb supplements grew by 14.5% in 2020 while combination-herb supplements grew by 24.7%. This growth was driven by supplements which addressed immunity, sleep support, and brain health, as well as mood and mental wellness, with those categories growing by 30%.

The planned acquisition provides BioLife a synergistic opportunity to diversify its current product portfolio into a new product line indicated for conditions related to gastrointestinal, endocrine, cardiovascular, immune, specialty, musculoskeletal, and men’s/women’s health.

“An acquisition of Health Box LLC would position BioLife Sciences as a disruptive entity within a booming market…[It] would offer the company instant access to meaningful revenue, an existing customer base, subject matter expertise, and innovative breakthroughs.”
- Justin De Four, CEO BioLife Sciences, on the motivation behind acquiring Health Box


Tight, Tight Float

BioLife has been trending on the quiet side of the news flow recently (with the exception being the Health Box LLC. letter of intent (LOI)), as it goes about building its business. Unlike most upstarts in the challenging covid economy, BioLife didn’t over-dilute to keep moving forward. Regulatory filings on OTC Markets show that the number of outstanding shares from November 2020 through August 2021 only increasing by 70,000 to hold at just 54.94 million, sans some convertible debt on the books. These filings also show that BLFE has only 3.97 million shares in the public float, an amazingly low number indicating the stock is very closely held by insiders.

With shares already in a multi-month upward trend and the news of the Health Box LOI, news of moving into a definitive agreement (along with any other new corporate developments) could send this under the radar healthcare stock racing even higher. COVID, and other viruses / pathogens are unfortunately not going away.  BioLife Sciences Inc. (OTCPK: BLFE) may be the perfect investor hedge during these unprecedented times.

About AllPennyStocks.com:

AllPennyStocks.com Media, Inc., founded in 1999, is one of North America’s largest and most comprehensive small-cap / penny stock financial portals. With Canadian and U.S. focused penny stock features and content, the site offers information for novice investors to expert traders. Outside of the countless free content available to visitors, AllPennyStocks.com Pro (premium service) caters to traders looking for that trading edge by offering monthly stock picks, daily penny stock to watch trade ideas, market commentary and more.

As a result of its commitment to journalistic excellence and abundance of information in a particular area of equity investing (micro-cap investing) where there aren’t many credible sources of information, AllPennyStocks.com continues to have one of the largest audiences of micro-cap investors on the internet.

Corporate Snapshot:
BioLife Sciences Inc.
Stock Symbol: BLFE
Stock Exchange: OTCPK
Sector: Healthcare
52 Week High: $2.5400
52 Week Low: $0.0618

Current Stock Quote / Chart / News: Click here

Information as of February 01, 2022

The coronavirus pandemic has raised awareness about health and wellness and what it takes to destroy resilient pathogens like those responsible for COVID-19 and all its Greek-alphabet-named variants. With 5.56 million deaths globally and over 331 million cases confirmed across all but four countries on Earth, essentially everyone on the planet is aware of the transmissibility and potential outcomes for contracting COVID-19.

From individuals to governments, standards and protocols are being implemented as part of “the new normal” to protect against viruses, fungi, parasites, and bacteria. Unsurprisingly, technology is playing a key role. These initiatives are right in the wheelhouse of BioLife Sciences Inc. (OTCPK: BLFE), an accelerator of companies and products with an initial focus on wellness, including antimicrobial technologies.

The flagship products in the BioLife product portfolio involve using leading-edge technologies, including copper infusion, to protect against pathogens. The company has also last month announced a transformational acquisition that will give revenue a shot in the arm.

Let’s Start with the Power of Copper

The phenomenon of copper-related health and wellness has been around for centuries. For starters, copper is an important mineral to the body taken in through a variety of foods and used in keeping nerve cells healthy, red blood cell production, immune system support, and more.

From an external perspective, the values of copper in many applications are trumpeted for the metal’s properties, including thermal regulation. Consider that NASA and armies around the world issue copper-impregnated clothing because of its insulation properties while remaining lightweight and breathable.

Blood circulation is another often heralded benefit of copper-infused products. During this time of the year with the NFL playoffs happening, it is not uncommon to see commercials where retired NFL legends serve as ambassadors for such products. Why? Because copper compression clothing is believed to be effective in alleviating poor circulation, which can help combat conditions like deep vein thrombosis, while reducing symptoms of inflammatory conditions, like arthritis. Again, thermal regulation is valuable in tissue repair and protection.

Another benefit of copper – and one that is more on point with warding off pathogens – is skin health. Copper is well known to promote healthy skin because of its antimicrobial properties, as well as its role in supporting collagen and elastin growth. In fact, the term “contact killing” originated with the knowledge that bacteria are destroyed when coming into contact with metallic copper surfaces. The antimicrobial benefits can be far reaching insomuch that destroying or limiting microbe growth under an array of conditions has positive benefits from preventing infections to purifying drinking water to eliminating foul odors.

There is also a growing body of evidence on the effectiveness of copper-impregnated fabric offering superior performance to today’s materials used in health services. So, while these products already have a place in healthcare, expanded uses supported by peer-reviewed clinical data present a unique opportunity for overlooked upside in a global environment where preventing and controlling pathogen transmissions is a top priority.

Mfusion: The Ultimate Coverage

To understand Mfusion requires the knowledge that many products today simply weave copper fibers into their products. This is not optimal, as it leaves gaps throughout the material. Mfusion infuses copper metal ions into every sub-bundle of the fabric filter, resulting in natural protection against bacteria and germs, which normally thrive when circulating in an enclosed room, or building.  The fabric helps to block out airborne particles, while any germs or viruses which are trapped in the filter fabric will come in contact with the copper ions and become deactivated over time.

BioLife’s Mfusion technology can apply to absolutely any textile, albeit face masks, bedding, pillow sheets, socks, gloves, shorts, t-shirts, hats, etc. Simply, if its cloth then BioLife can infuse it and amplify and create natural antimicrobial, antiviral, anti-odor, and antifungal benefits. The potential applications are wide ranging from fighting jock itch and acne to anti-aging possibilities.

Copper-Infused Facial Masks

Facing a global pandemic, BioLife put its technology to work, launching a line of copper-infused face masks as an answer to one of the most debated topics in America of whether or not masks work. Understand that with the cloth masks that most people wear daily, pathogens can live for days. Conversely, masks infused with copper provide continuous protection, while potentially providing several health benefits to the skin through copper’s anti-inflammatory and regenerative properties.

BioLife manufactures its face masks in North America and offers them in cotton and polyester blends in wholesale quantities.

Antimicrobial Air Filters: Masks for a House or Business

BioLife also launched a new antimicrobial air filter based upon its proprietary Mfusion technology. The BioLife Antimicrobial Air Filters are designed to durably clean the air and fight against airborne bacteria and viruses, providing consumers with the ability to help sanitize the air in their homes or workspaces for months at a time.

Mfusion technology leverages the natural antimicrobial benefits of copper ions, which have been shown to kill 99.99% of bacteria, fungi, and viruses.

BioLife Making Air Travel Safer

It used to be that most people were afraid to fly because of the (albeit miniscule) risk of a crash. Today, those fears have been replaced by virus concerns. BioLife entered this space in November 2020, inking an agreement with FLYGTA, an Ontario-based operator of a fleet of aircraft serving private travel, air ambulance, cargo, tourism, and aviation technologies, to become the exclusive supplier of electrostatic disinfection and cleaning services. Per the pact, BioLife agreed to conduct cleaning and disinfecting services for FLYGTA’s aircraft fleet and private lounges, operating out of district airports throughout Ontario, including Toronto's Billy Bishop Airport.

BioLife’s sanitation technology is designed to control bacterial, viral, and fungal populations on high-touch, high-traffic surfaces by reducing the number of germs on the treated areas. The company’s electrostatic systems turn disinfectant liquids into fine mist aerosols, subsequently applying a charge to each droplet so that they are attracted to surfaces through electrostatic forces greater than gravity. The result is a wrap-around effect for complete coverage, even in areas that would generally be difficult to clean.

The technology is scalable and versatile, able to be used with essentially any water-based disinfectant to meet the customer’s needs. With FLYGTA, BioLife used a natural essential oil and water-based sanitation solution known to be effective against SARS-CoV-2 (the coronavirus responsible for COVID-19) and strain 229E, a common human coronavirus. Customers can rest assured that while effective as a broad spectrum surface disinfectant, the product is also non-toxic, biodegradable, non-corrosive, odorless, and colorless, in other words: potent and environmentally-friendly.

“We are ready for the new wave of travel with this added safety measure. Antimicrobial protection is the smartest way forward.”
- Chris Nowrouzi, CEO of FLYGTA, on the BioLife agreement

BioLife Buying Health Box

On January 25th, BioLife said that it had inked a Letter of Intent to acquire Health Box LLC, an Arizona-based company specialized in advanced orthomolecular medicine and natural health products development and research. More precisely, Health Box provides a diverse mix of advanced orthomolecular and natural health products founded in extensive research focused on medicinal botanicals, micronutrients, dietary supplements, proprietary herbal blends, and apothecary style subscription services. Further, Health Box is an expert in the development of tinctures, oils, vitamins and hemp-derived cannabidiol (CBD) products.

“Orthomolecular” is a term coined in 1968 by molecular biologist and two-time Nobel Prize winner Dr. Linus Pauling. Coupling “ortho” (Green for “correct” or “right”) and “molecule, the word literally means the “right molecule.” The practice of orthomolecular medicine is characterized by evidence-based formulations providing the body with optimal amounts of substances natural to the body for the purpose of preventing and treating diseases and conditions.

The company is in the thick of a global herbal supplements market that has been accelerating amid heightened health and wellness awareness, where consumers have become increasingly proactive at bolstering immunity and looking for safe, natural alternatives to conventional drugs to stave off pathogens.

According to the company, the global herbal supplements market is projected to reach $86.74 billion by 2022 after 6.8% from 2016 to 2022. Single herb supplements grew by 14.5% in 2020 while combination-herb supplements grew by 24.7%. This growth was driven by supplements which addressed immunity, sleep support, and brain health, as well as mood and mental wellness, with those categories growing by 30%.

The planned acquisition provides BioLife a synergistic opportunity to diversify its current product portfolio into a new product line indicated for conditions related to gastrointestinal, endocrine, cardiovascular, immune, specialty, musculoskeletal, and men’s/women’s health.

“An acquisition of Health Box LLC would position BioLife Sciences as a disruptive entity within a booming market…[It] would offer the company instant access to meaningful revenue, an existing customer base, subject matter expertise, and innovative breakthroughs.”
- Justin De Four, CEO BioLife Sciences, on the motivation behind acquiring Health Box


Tight, Tight Float

BioLife has been trending on the quiet side of the news flow recently (with the exception being the Health Box LLC. letter of intent (LOI)), as it goes about building its business. Unlike most upstarts in the challenging covid economy, BioLife didn’t over-dilute to keep moving forward. Regulatory filings on OTC Markets show that the number of outstanding shares from November 2020 through August 2021 only increasing by 70,000 to hold at just 54.94 million, sans some convertible debt on the books. These filings also show that BLFE has only 3.97 million shares in the public float, an amazingly low number indicating the stock is very closely held by insiders.

With shares already in a multi-month upward trend and the news of the Health Box LOI, news of moving into a definitive agreement (along with any other new corporate developments) could send this under the radar healthcare stock racing even higher. COVID, and other viruses / pathogens are unfortunately not going away.  BioLife Sciences Inc. (OTCPK: BLFE) may be the perfect investor hedge during these unprecedented times.

About AllPennyStocks.com:

AllPennyStocks.com Media, Inc., founded in 1999, is one of North America’s largest and most comprehensive small-cap / penny stock financial portals. With Canadian and U.S. focused penny stock features and content, the site offers information for novice investors to expert traders. Outside of the countless free content available to visitors, AllPennyStocks.com Pro (premium service) caters to traders looking for that trading edge by offering monthly stock picks, daily penny stock to watch trade ideas, market commentary and more.

As a result of its commitment to journalistic excellence and abundance of information in a particular area of equity investing (micro-cap investing) where there aren’t many credible sources of information, AllPennyStocks.com continues to have one of the largest audiences of micro-cap investors on the internet.


Forward Looking Statements

This report includes forward-looking statements that reflect current expectations about its future results, performance, prospects and opportunities. BioLife Sciences Inc. has tried to identify these forward-looking statements by using words and phrases such as "may," "will," "expects," "anticipates," "believes," "intends," "estimates," "plan," "should," "typical," "preliminary," "we are confident" or similar expressions. These forward-looking statements are based on information currently available and are subject to a number of risks, uncertainties and other factors that could cause BioLife Sciences Inc.'s actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. These risks, uncertainties and other factors include, without limitation, the Company's growth expectations and ongoing funding requirements, and specifically, the Company's growth prospects with scalable customers, and those outlined above. Other risks include the Company's limited operating history, the Company's history of operating losses, consumers' acceptance, the Company's use of licensed technologies, risk of increased competition, the potential need for additional financing, the terms and conditions of any financing that is consummated, the limited trading market for the Company's securities, the possible volatility of the Company's stock price, the concentration of ownership, and the potential fluctuation in the Company's operating results.

Disclaimer

AllPennyStocks.com feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. This is an advertisement for BioLife Sciences Inc. The purpose of this advertisement, like any advertising, is to provide coverage and awareness for the company. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.

© 1999-2022AllPennyStocks.com Media, Inc. All rights reserved. AllPennyStocks.com is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views; opinions or recommendations contained herein will produce profitable results. AllPennyStocks.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), AllPennyStocks.com will disclose in its disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the AllPennyStocks.com web site. AllPennyStocks.com has been compensated nineteen thousand dollars by the company for its efforts in presenting the BLFE profile on its web site and distributing it to its database of subscribers as well as other services. AllPennyStocks.com may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. Information presented on our web site and within our reports contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as "expects", "will," "anticipates," "estimates, "believes," or that by statements indicating certain actions "may," "could," or "might" occur. THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

Other Penny Stock Movers

Shares on the Rise As Gas Production Starts
Subsidiary Deal With Lowe's Inc. Sends Parent Shares Flying
New Order Announcement Causes Significant Buying Pressure
Most Popular
FREE Newsletter


Back to Top